{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.8","upperLimit":"51.6","value":"41.4"}]}],"title":"PFS rate at 6 months by ICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.1","upperLimit":"47.2","value":"37.7"}]}],"title":"PFS rate at 6 months by Investigator assessment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.6","upperLimit":"41.8","value":"30.9"}]}],"title":"PFS rate at 12 months by ICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"36.7","value":"26.5"}]}],"title":"PFS rate at 12 months by Investigator assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Percentage of participants alive and progression-free at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"OG000","title":"T-DXd"}],"paramType":"NUMBER","populationDescription":"The FAS consisted of all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"At Months 6 and 12","title":"Percentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1.1 Using ICR and Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}